P2, N=13, Terminated, NYU Langone Health | N=23 --> 13 | Completed --> Terminated; Study was terminated early by the drug sponsor due to slow accrual and a change in the company's drug development priorities

2 months ago

Enrollment change • Trial termination

Opdivo (nivolumab) • cabiralizumab (BMS-986227) • BMS-986253

2ms

A novel anti-PD-L1/IL-8 bispecific antibody BP2402 enhances antitumor immunity and modulates inflammatory signaling in triple-negative breast cancer mice model. (PubMed, J Transl Med)

These results indicate that dual targeting of PD-L1 and IL-8 pathways represents a promising therapeutic strategy for TNBC. The bispecific antibody approach offers superior therapeutic potential by simultaneously modulating immune checkpoints, inflammatory signaling, and angiogenesis, effectively addressing resistance mechanisms. Additional preclinical optimization and clinical studies are required to fully assess the therapeutic potential of this novel immunotherapeutic approach.

2 months ago

Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker

CXCL8 (Chemokine (C-X-C motif) ligand 8) • JAK1 (Janus Kinase 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)

Tecentriq (atezolizumab) • BMS-986253

2ms

The Interleukin-8-CXCR1/2 Axis as a Therapeutic Target in Peritoneal Carcinomatosis. (PubMed, Curr Oncol)

IL-8 targeting agents such as monoclonal antibodies (BMS-986253) and small-molecule inhibitors (SX-682, AZD5069, navarixin) have shown efficacy in mitigating tumor growth and improving the efficacy of immune checkpoint inhibitors. In this review, we discuss the influence of the IL-8/CXCR1/CXCR2 axis within the peritoneal immune environment in PC and highlight recent work using IL-8 or CXCR1/CXCR2 blockade as a therapeutic strategy for PC. Continued research into the peritoneal immune microenvironment and the development of targeted therapies are essential for improving the management and prognosis of PC, potentially enhancing antitumor immunity and patient outcomes.

2 months ago

Review • Journal

IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • CXCR2 (Chemokine (C-X-C motif) receptor 2)

SX-682 • AZD5069 • BMS-986253 • navarixin (MK-7123)

3ms

NICHE: Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (clinicaltrials.gov)

P2, N=353, Recruiting, The Netherlands Cancer Institute | N=268 --> 353 | Trial completion date: Dec 2024 --> Mar 2032 | Trial primary completion date: Dec 2024 --> Mar 2032

3 months ago

Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition

MSI-H/dMMR

Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016) • BMS-986253 • celecoxib oral

4ms

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas (clinicaltrials.gov)

P2, N=76, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting --> Active, not recruiting

4 months ago

Enrollment closed • IO biomarker

Opdivo (nivolumab) • cyclophosphamide • BMS-986253 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • urelumab (BMS-663513)

7ms

Nivolumab Combined With BMS-986253 in HCC Patients (clinicaltrials.gov)

P2, N=23, Completed, NYU Langone Health | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Jan 2025

7 months ago

Trial completion • Trial completion date

Opdivo (nivolumab) • cabiralizumab (BMS-986227) • BMS-986253

8ms

Spark2: Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca (clinicaltrials.gov)

P2, N=24, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Apr 2026 --> Sep 2026 | Trial primary completion date: Apr 2025 --> Apr 2026

8 months ago

Trial completion date • Trial primary completion date

Opdivo (nivolumab) • BMS-986253

8ms

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas (clinicaltrials.gov)

P2, N=76, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Aug 2026 --> May 2026

8 months ago

Trial completion date • IO biomarker

Opdivo (nivolumab) • cyclophosphamide • BMS-986253 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • urelumab (BMS-663513)

11ms

GCO 19-1754: Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)

P2, N=48, Active, not recruiting, Icahn School of Medicine at Mount Sinai | Completed --> Active, not recruiting | Trial completion date: Nov 2023 --> Dec 2025 | Trial primary completion date: Nov 2023 --> Dec 2025

11 months ago

Enrollment closed • Trial completion date • Trial primary completion date

Opdivo (nivolumab) • BMS-813160 • BMS-986253

12ms

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas (clinicaltrials.gov)

P2, N=76, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Dec 2024 --> Aug 2025

12 months ago

Trial completion date • Trial primary completion date • IO biomarker

CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • TNFRSF9 (TNF Receptor Superfamily Member 9) • GZMB (Granzyme B) • IL17A (Interleukin 17A)

CD8 expression

Opdivo (nivolumab) • cyclophosphamide • BMS-986253 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • urelumab (BMS-663513)

1year

Spark2: Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca (clinicaltrials.gov)

P2, N=24, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Aug 2024 --> Apr 2025

1 year ago

Trial primary completion date • Combination therapy • Surgery

Opdivo (nivolumab) • BMS-986253